One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Considering Race and Ethnicity in Covid Risk Assessments — Legal Concerns and Possible Solutions
Timothy S. Jost, J.D.
doi : 10.1056/NEJMp2206524
Vol. 387 No. 6
Understanding Covid Vaccine Efficacy over Time — Bridging a Gap Between Public Health and Health Care
Isaac Kohane, M.D., Ph.D., and Gilbert S. Omenn, M.D., Ph.D.
doi : 10.1056/NEJMp2201084
Noncompete Agreements — The Need for a Refresh
Samyukta Mullangi, M.D., M.B.A., Mohit Agrawal, M.S., M.B.A., and Barak Richman, J.D., Ph.D.
doi : 10.1056/NEJMp2205013
Bringing Sickle-Cell Treatments to Children in Sub-Saharan Africa
Albert E. Zhou, M.D., Ph.D., and Mark A. Travassos, M.D.
doi : 10.1056/NEJMp2201763
The Critical Shortage of Iodinated Contrast Material — Will Value Prevail?
Long H. Tu, M.D., Jennifer E. Miller, Ph.D., and Howard P. Forman, M.D., M.B.A.
doi : 10.1056/NEJMp2206996
Teclistamab in Relapsed or Refractory Multiple Myeloma
Philippe Moreau, M.D., Alfred L. Garfall, M.D., Niels W.C.J. van de Donk, M.D., Ph.D., Hareth Nahi, M.D., Ph.D., Jesús F. San-Miguel, M.D., Ph.D., Albert Oriol, M.D., Ph.D., Ajay K. Nooka, M.D., Thomas Martin, M.D., Laura Rosinol, M.D., Ajai Chari, M.D., Lionel Karlin, M.D., Lotfi Benboubker, M.D.,
doi : 10.1056/NEJMoa2203478
Teclistamab is a T-cell–redirecting bispecific antibody that targets both CD3 expressed on the surface of T cells and B-cell maturation antigen expressed on the surface of myeloma cells. In the phase 1 dose-defining portion of the study, teclistamab showed promising efficacy in patients with relapsed or refractory multiple myeloma.
Removal of Small, Asymptomatic Kidney Stones and Incidence of Relapse
Mathew D. Sorensen, M.D., Jonathan D. Harper, M.D., Michael S. Borofsky, M.D., Tariq A. Hameed, M.D., Kimberly J. Smoot, M.A., Barbara H. Burke, B.S., Branda J. Levchak, B.S., James C. Williams, Jr., Ph.D., Michael R. Bailey, Ph.D., Ziyue Liu, Ph.D., and James E. Lingeman, M.D.
doi : 10.1056/NEJMoa2204253
The benefits of removing small (≤6 mm), asymptomatic kidney stones endoscopically is unknown. Current guidelines leave such decisions to the urologist and the patient. A prospective study involving older, nonendoscopic technology and some retrospective studies favor observation. However, published data indicate that about half of small renal stones left in place at the time that larger stones were removed caused other symptomatic events within 5 years after surgery.
Fazirsiran for Liver Disease Associated with Alpha1-Antitrypsin Deficiency
Pavel Strnad, M.D., Mattias Mandorfer, M.D., Ph.D., Gourab Choudhury, M.D., William Griffiths, M.D., Christian Trautwein, M.D., Rohit Loomba, M.D., Thomas Schluep, Sc.D., Ting Chang, Ph.D., Min Yi, Ph.D., Bruce D. Given, M.D., James C. Hamilton, M.D., Javier San Martin, M.D.,
doi : 10.1056/NEJMoa2205416
Alpha1-antitrypsin (AAT) deficiency results from carriage of a homozygous SERPINA1 “Z� mutation (proteinase inhibitor [PI] ZZ). The Z allele produces a mutant AAT protein called Z-AAT, which accumulates in hepatocytes and can lead to progressive liver disease and fibrosis. This open-label, phase 2 trial investigated the safety and efficacy of fazirsiran, an RNA interference therapeutic, in patients with liver disease associated with AAT deficiency.
Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 Years of Age
Sharon H.X. Tan, M.P.H., Alex R. Cook, Ph.D., Derrick Heng, M.Phil., Benjamin Ong, M.B., B.S., David C. Lye, M.B., B.S., and Kelvin B. Tan, Ph.D.
doi : 10.1056/NEJMoa2203209
Since it was first identified in early November 2021, the B.1.1.529 (omicron) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread quickly and replaced the B.1.617.2 (delta) variant as the dominant variant in many countries. Data on the real-world effectiveness of vaccines against the omicron variant in children are lacking.
Lupus Pernio in Sarcoidosis
Weijian Zhang, M.D., and Zhuo-Li Zhang, M.D., Ph.D.
doi : 10.1056/NEJMicm2118330
Hair Repigmentation Induced by Nilotinib
Camille C.B. Kockerols, M.D., and Peter E. Westerweel, M.D., Ph.D.
doi : 10.1056/NEJMicm2119953
Case 24-2022: A 31-Year-Old Man with Perianal and Penile Ulcers, Rectal Pain, and Rash
Nesli Basgoz, M.D., Catherine M. Brown, D.V.M., M.P.H., Sandra C. Smole, Ph.D., H.C.L.D. (A.B.B.), Lawrence C. Madoff, M.D., Paul D. Biddinger, M.D., Joshua J. Baugh, M.D., M.P.P., M.H.C.M., and Erica S. Shenoy, M.D., Ph.D.
doi : 10.1056/NEJMcpc2201244
T-Cell Engagers — Modern Immune-Based Therapies for Multiple Myeloma
Sham Mailankody, M.B., B.S., and Ola Landgren, M.D., Ph.D.
doi : 10.1056/NEJMe2209692
Preemptive Removal of Small, Asymptomatic Kidney Stones
David S. Goldfarb, M.D.
doi : 10.1056/NEJMe2208287
Reviewers for the Journal, January–June 2022
Eric J. Rubin, M.D., Ph.D.
doi : 10.1056/NEJMe2209235
Audio Interview: Combating Covid-19 Today and Tomorrow
Eric J. Rubin, M.D., Ph.D., Lindsey R. Baden, M.D., and Stephen Morrissey, Ph.D.
doi : 10.1056/NEJMe2210673
Screening for Atrial Fibrillation in Asymptomatic Older Adults
Clement Lee, M.D., MÃ¥rten Rosenqvist, M.D., and John Mandrola, M.D.
doi : 10.1056/NEJMclde2203726
